Противовоспалительная активность и профиль безопасности эторикоксиба по результатам рандомизированных исследований

1. Chan FKL, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Antiinflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103: 2908–18.
2. Lanza FL, Chan FKL, Quigley EMM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
3. Croom KF, Siddiqui MA. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs 2009; 69 (11): 1513–32.
4. Dallob A, Hawkey CJ, Greenberg H et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol 2003; 43: 573–85.
5. Riendeau D, Percival MD, Brideau C et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296 (2): 558–66.
6. Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr MedRes Opin 2003; 19 (8): 725–36.
7. Wiesenhutter CW, Boice JA, Ko A et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80 (4): 470–9.
8. Puopolo A, Boice JA, Fidelholtz JL et al. A randomized placebocontrolled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage 2007; 15 (12): 1348–56.
9. Fisher CA, Curtis SP, Resnick H et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks [abstract no. 495]. Arthritis Rheum 2001; 44 (9 Suppl.): S135.
10. Leung AT, Malmstrom K, Gallacher AE et al. Efficacy and tolerability profile of etoricoxib: a randomized, doubleblind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18 (2): 49–58.
11. Bingham 3rd CO, Sebba AI, Rubin BR et al. Efficacy and safety of etoricoxib 30mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebocontrolled, non-inferiority studies. Rheumatol (Oxford) 2007; 46 (3): 496–507.
12. Stam W, Gaugris S, Jansen J. Efficacy of etoricoxib in the treatment of osteoarthritis as compared to non-selective NSAIDS: a Bayesian meta-analysis [abstract no. THU0438]. The Annual European Congress of Rheumatology. Barcelona 2007; 13–16.
13. Moore RA, Moore OA, Derry S et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis Epub 2009; 12 (on-line, in press).
14. van der Heijde D, Baraf HS, Ramos-Remus C et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fiftytwo-week, randomized, controlled study. Arthritis Rheum 2005; 52 (4): 1205–15.
15. Schumacher Jr HR, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324 (7352): 1488–92.
16. Rubin BR, Burton R, Navarra S et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50 (2): 598–606.
17. Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; 2: CD004309.
18. Cannon CP, Curtis SP, Bolognese JA et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006; 152 (2): 237–45.
19. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368 (9549): 1771–81.
20. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009; 48 (4): 425–32.
21. Baraf HS, Fuentealba C, Greenwald M et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007; 34 (2): 408–20.
22. Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 2008; 67 (3): 315–22.
23. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet 2007; 369 (9560): 465–73.
24. Ramey DR, Watson DJ, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. nonselective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21 (5): 715–22.
25. Watson DJ, Bolognese JA, Yu C et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20 (12): 1899–908.
26. Aldington R, Shirtcliffe S, Weatherall P et al. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 2005; 118 (1223): U1684.
27. Curtis SP, Ko AT, Bolognese JA et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin 2006; 22 (12): 2365–74.
28. van der Linden MW, van der Bij S, Welsing P et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs Ann Rheum Dis 2009; 68: 668–73.
29. Moore A, Phillips C, Hunsche E et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004; 22 (10): 643–60.
30. Etoricoxib 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2009 Mar 5].
31. Malmstrom K, Kotey P, Coughlin H et al. A randomized, doubleblind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain 2004; 20(3):147–55.
32. Malmstrom K, Kotey P, Cichanowitz N et al. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol Obstet Invest 2003; 56 (2): 65–9.
33. Pallay RM, Seger W, Adler JL et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3-month, randomized, controlled trial. Scand J Rheumatol 2004; 33(4): 257–66.